The Functional Service Providers (FSP) Market is estimated to be valued at US$ 15.72 Bn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Functional service providers (FSPs) offer a range of services to pharmaceutical, biotechnology and medical device companies across different functions such as clinical research, medical affairs, regulatory affairs, pharmacovigilance and market access. The key services provided by FSPs includes clinical trial management, biostatistics, regulatory consulting, medical writing, and safety evaluation. FSPs aim to reduce costs and improve efficiency for clients by taking over specific business functions. They leverage expertise across various therapeutic areas to provide customized solutions. Emerging areas such as real-world evidence, healthcare economic evaluation and digital services are also gaining traction.
Market Dynamics:
The growth of the Functional Service Providers (FSP) Market is driven by the rising outsourcing of clinical trials and other R&D functions by pharmaceutical and biotechnology companies. Outsourcing non-core activities helps companies focus on drug development and launch, thereby accelerating their process. In addition, increasing complexity of clinical trials and stringent regulatory requirements are prompting sponsors to leverage capabilities of specialized providers. Further, the digital transformation of clinical trials with tools such as electronic data capture and eConsent is augmenting the demand for FSPs having relevant technical expertise. However, higher costs of outsourcing and data privacy & security concerns pose challenges to the market.
Segment Analysis
The Functional Service Providers (FSP) market can be segmented into clinical research services, consulting services and medical writing services. Clinical research services forms the dominant segment as it contributes to more than 50% of the total FSP market revenues. The clinical research services segment is further divided into clinical trial management, biopharmaceutical services and medical device and diagnostics services. Clinical trial management dominates clinical research services segment as more pharmaceutical and biopharmaceutical companies outsource clinical trial management to reduce costs and risks.
PEST Analysis
Political: Regulations such as GCP and regional regulations influence outsourcing from sponsors to FSPs. Stringent regulations drive the need for specialized third-party service providers.
Economic: Rising R&D costs in drug development compel biopharma companies to outsource non-core functions to FSPs to reduce costs.
Social: Growing disease prevalence increases drug development activities propelling demand for specialized outsourcing partners across clinical research and development.
Technological: Advancements in e-clinical technologies facilitate remote and decentralized clinical trials models enhancing outsourcing to global FSP networks.
Key Takeaways
The Functional Service Providers (FSP) Market Size is expected to witness high growth, exhibiting CAGR of 8.0% over the forecast period, due to increasing R&D costs and complexities in clinical research. The market size for 2023 is US$ 15.72 Bn.
North America dominates the global FSP market currently owing to presence of majority global FSP companies such as QuintilesIMS, PRA Health Sciences, and PPD in the region. However, Asia Pacific is expected to witness highest growth during the forecast period due to low-cost operations and expanding biopharmaceutical industries in countries like China and India stimulating FSP activities.
Key players operating in the FSP market are QuintilesIMS (now IQVIA), Parexel International Corporation, ICON plc, PRA Health Sciences, Covance Inc., Charles River Laboratories International Inc., Syneos Health, Pharmaceutical Product Development, LLC (PPD), Medpace Holdings, Inc., LabCorp (Laboratory Corporation of America Holdings), Wuxi AppTec, inVentiv Health (now Syneos Health), PAREXEL International (now part of PPD), Accenture, Cognizant. QuintilesIMS, Parexel International, PRA Health Sciences, and Covance Inc. currently dominate the FSP market owing to their expertise in various clinical research and development services as well as global network across major markets.
Read More: https://www.ukwebwire.com/functional-service-providers-market-scope/
